This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:protocol:olmesartan:safety [06.11.2019] – [Data supporting the safety of higher than typical dosing frequencies] sallieq | home:protocol:olmesartan:safety [07.19.2019] – [Safety of olmesartan (Benicar)] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Safety of olmesartan (Benicar) ====== | ====== Safety of olmesartan (Benicar) ====== | ||
+ | |||
+ | < | ||
Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home: | Some patients and healthcare providers have expressed concerns about the safety of higher than typical [[home: | ||
Line 122: | Line 124: | ||
[[http:// | [[http:// | ||
+ | |||
+ | With the halt of reimbursement of olmesartan, there was a decrease in the prescription of ARB in France. When olmersartan was replaced by another ARB, a worse blood pressure control was observed in treated hypertensive patients. | ||
+ | |||
+ | |||
+ | ==== Enteropathy ==== | ||
+ | |||
+ | The incidence of this adverse drug reaction is not entirely clear, although it is thought to be rare. | ||
+ | (({{pubmed> | ||
+ | |||
+ | |||
+ | Seven cases (2.8%) reported recurrence of symptoms after restarting olmesartan (({{pubmed> | ||
+ | |||
+ | Although enteropathy is rare, clinicians should remain vigilant of this potential adverse event even years after medication initiation. | ||
+ | (({{pubmed> | ||
+ | |||
+ | results suggest that SMEEDS formulation improves dissolution and oral bioavailability of OM while reducing adverse effects (celiac-like enteropathy or diarrhea ). (({{pubmed> | ||
+ | |||
+ | ==== Collagenous enteritis, a genetic problem? ==== | ||
+ | |||
+ | Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis. | ||
+ | |||
+ | All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications, | ||
+ | |||
+ | Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. | ||
===== Notes and comments ===== | ===== Notes and comments ===== |